Solventum Corporation Reports Strong Q1 2025, Stock Rises Post-Results

Maplewood, Minnesota-based Solventum Corporation (SOLV) is a global healthcare company that develops, manufactures, and commercializes solutions addressing critical customer and patient needs. With a market cap of $12.3 billion, the company operates through segments including Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Stock Performance Relative to Market

Over the past 52 weeks, SOLV shares have outperformed the broader market. During this period, SOLV stock increased by 16.8%, while the S&P 500 Index ($SPX) saw an 11.5% gain. Year-to-date, SOLV shares are also up 10.4%, compared to the modest returns of the SPX.

In addition, Solventum has notably outpaced the SPDR S&P Health Care Equipment ETF (XHE), which experienced a 6.2% drop over the past year and a 7% dip in 2025.

Q1 2025 Results and Future Outlook

Following the release of its Q1 2025 results on May 8, Solventum’s stock rose 5.4%. The company reported sales of $2.1 billion, reflecting a 2.7% year-over-year increase. This growth was driven by 3.4% and 3.8% increases in its MedSurg and Health Information Systems segments, respectively. Importantly, revenues also exceeded analysts’ expectations of $2 billion. Although adjusted EPS fell by 35.6% year-over-year to $1.34, it surpassed the analysts’ estimate of $1.19.

Furthermore, Solventum increased its fiscal 2025 organic sales growth guidance to a range of 1.5% to 2.5%, up from the previous 1.0% to 2.0%. This revision has fueled investor confidence.

For the current fiscal year ending in December 2025, analysts project SOLV’s adjusted EPS will decline nearly 16.9% year-over-year to $5.57. The company has a mixed earnings surprise history, beating estimates in three of the past four quarters while falling short on one occasion.

Analyst Ratings and Price Targets

Among the ten analysts covering SOLV, the consensus rating is a “Hold,” based on one “Strong Buy,” eight “Holds,” and one “Strong Sell.” This rating stability has persisted in recent months.

On May 9, Piper Sandler (PIPR) analyst Jason Bednar lowered SOLV’s price target to $78 while maintaining an “Overweight” rating on the stock.

Currently, Solventum’s mean price target stands at $80.28, indicating a potential upside of 10.1% from current levels. The highest price target from analysts, at $88, suggests a significant upside potential of 20.6%.

On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are solely for informational purposes. For more information, please view the Barchart Disclosure Policy here.

The views expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.